Bolsas y Mercados Españoles
Company
search
LABORATORIOS FARMACEUTICOS ROVI, S.A.
AddressCL JULIAN CAMARILLO 35, 28037 MADRID 
Listed Capital3,240,969.42 Euros

 


LABORATORIOS ROVI
ISINES0157261019 TickerROVI Nominal0.06 MarketContinuous Market Admitted Capital3,240,969.42 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
07/12/2022Close36.480036.34000.3936.480036.660036.200036.447593,8673,421,216.60
06/12/2022Close36.340036.9400-1.6236.340036.880036.140036.4014163,5325,952,801.24
X
07/12/2022 17:37:07
BidAsk
OrdersVolumePricePriceVolumeOrders
12336.460036.48001,5555
Data Delayed 15 minutes.

Last pay
TypeEx-datePayment DateConcept
Dividend05/07/202207/07/2022Annual 2021

Last split
DateEquivalence
 

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
01/11/201899 x 10,000Premium


 2022
until 6/12
2021202020192018
Capitalisation *
(thousands of euros)
1,962,9474,137,8902,125,0141,368,083978,403
Shares
(x 1,000)
54,01656,06956,06956,06956,069
Period Close Price
(euros)
36.340073.800037.900024.400017.4500
Period Last Price
(euros)
36.340073.800037.900024.400017.4500
Period High Price
(euros)
74.900074.200042.500025.500018.1500
Period Low Price
(euros)
35.720038.000020.000016.900014.8000
Volume
(thousands of shares)
38,98321,43714,1505,4009,971
Turnover
(thousands of euros)
2,185,9681,165,627429,997109,782153,179

Profile

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already present in 89 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe and it is already marketed in 38 countries. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es

Source: Issuing company.
07/12/2022 00:01:49

Video Gallery

Research

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © BME 2022